Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway; A Retrospective, Observational Study to Evaluate the Impact on Disease Control in Patients With Asthma and/or Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms BufoSwitch
- Sponsors Orion Pharma
- 16 Sep 2021 Status changed from recruiting to discontinued as the target recruitment was not reached.
- 10 Aug 2021 Planned End Date changed from 30 Apr 2021 to 30 Dec 2021.
- 10 Aug 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Dec 2021.